Drug Profile

Research programme: antimicrobial therapeutics - SNIPR Biome

Alternative Names: CRISPR-Cas gene editing therapeutics - SNIPR Biome

Latest Information Update: 04 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SNIPR Biome
Class Antibacterials; DNA; Gene therapies
Mechanism of Action Bacterial DNA inhibitors; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Research Gastrointestinal disorders
No development reported Bacterial infections

Most Recent Events

28 Jun 2024 Early research in Gastrointestinal disorders in Denmark (unspecified route)
01 Aug 2022 SNIPR Biome has patent protection for CRISPR/Cas technology in USA
28 Nov 2021 No recent reports of development identified for preclinical development in Bacterial-infections in Denmark (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com